![Benjamin Scruggs](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Benjamin Scruggs
Vorstandsvorsitzender bei
Altis Biosystems, Inc.
Profil
Benjamin Scruggs currently works at Altis Biosystems, Inc., as Chief Executive Officer & Director, Veralox Therapeutics, Inc., as Director from 2021, IMMvention Therapeutix, Inc., as Director, Tune Therapeutics, Inc., as Senior Director from 2022, and Hatteras Venture Partners, as Partner from 2025.
Dr. Scruggs received his doctorate degree in 2012 from Washington University in St. Louis and undergraduate degree in 2006 from Vanderbilt University.
Aktive Positionen von Benjamin Scruggs
| Unternehmen | Position | Beginn |
|---|---|---|
Hatteras Venture Partners
 Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners invests in companies located in the United States. The firm targets companies operating in the fields of biopharmaceuticals, medical devices, diagnostics, healthcare IT and human medicine. It provides financing for seed and early stage capital requirements and also makes co-investments. | Private Equity Investor | 01.01.2021 |
IMMvention Therapeutix, Inc.
 IMMvention Therapeutix, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies | Direktor/Vorstandsmitglied | - |
Veralox Therapeutics, Inc.
 Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery and development services for clinical stage company | Direktor/Vorstandsmitglied | 01.06.2021 |
Tune Therapeutics, Inc.
 Tune Therapeutics, Inc. BiotechnologyHealth Technology Operates epigenome treatment medicines | Direktor/Vorstandsmitglied | 01.01.2022 |
Altis Biosystems, Inc.
 Altis Biosystems, Inc. Pharmaceuticals: MajorHealth Technology Develops stem cell technology designed to recreate the human intestinal epithelium and colonic epithelium for compound screening and microbiome research | Vorstandsvorsitzender | 01.02.2023 |
Ausbildung von Benjamin Scruggs
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
98
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Washington University in St. Louis
 Washington University in St. Louis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vanderbilt University
 Vanderbilt University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners invests in companies located in the United States. The firm targets companies operating in the fields of biopharmaceuticals, medical devices, diagnostics, healthcare IT and human medicine. It provides financing for seed and early stage capital requirements and also makes co-investments. | Finance |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery and development services for clinical stage company | Health Technology |
Altis Biosystems, Inc.
Altis Biosystems, Inc. Pharmaceuticals: MajorHealth Technology Develops stem cell technology designed to recreate the human intestinal epithelium and colonic epithelium for compound screening and microbiome research | Health Technology |
IMMvention Therapeutix, Inc.
IMMvention Therapeutix, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies | Health Technology |
Tune Therapeutics, Inc.
Tune Therapeutics, Inc. BiotechnologyHealth Technology Operates epigenome treatment medicines | Health Technology |
